Sophiya Karki1, Shahid Umar2, Anup Kasi3. 1. Department of Medicine, University of Kansas School of Medicine, Kansas City, KS, U.S.A. 2. Department of Medicine, Division of Surgery, Kansas University Medical Center, Kansas City, KS, U.S.A. 3. Department of Medicine, Division of Medical Oncology, Kansas University Medical Center, Kansas City, KS, U.S.A.
Abstract
PURPOSE OF REVIEW: Colorectal cancer (CRC) is the second leading cause of cancer-associated deaths in the United States, with most metastatic cases subsequently turning refractory to standard chemotherapy. One of the promising current interventions is immunotherapy that relies on harnessing the body's immune mechanisms to kill the cancer cells. The aim of this review is to highlight the implications of single versus combination immunotherapy and identify the molecular features and mutations that enhance or deter responsiveness. RECENT FINDINGS: Based on current findings, responsiveness is associated with deficiency of mismatch repair (dMMR) genes or presence of microsatellite instability (MSI-high), with high immunoscore and tumor-mutational burden contributing to better efficacy while BRAF mutation conferring no significant effect. Combination immunotherapy demonstrates better efficacy in treating MSI-high CRC compared to single agent immunotherapy or chemotherapy. SUMMARY: Given improved responsiveness and overall survival, there is potential for immunotherapy to change the standard of care for metastatic CRC. Furthermore, stratifying the patients by their molecular features and mutation status is critical for establishing care.
PURPOSE OF REVIEW: Colorectal cancer (CRC) is the second leading cause of cancer-associated deaths in the United States, with most metastatic cases subsequently turning refractory to standard chemotherapy. One of the promising current interventions is immunotherapy that relies on harnessing the body's immune mechanisms to kill the cancer cells. The aim of this review is to highlight the implications of single versus combination immunotherapy and identify the molecular features and mutations that enhance or deter responsiveness. RECENT FINDINGS: Based on current findings, responsiveness is associated with deficiency of mismatch repair (dMMR) genes or presence of microsatellite instability (MSI-high), with high immunoscore and tumor-mutational burden contributing to better efficacy while BRAF mutation conferring no significant effect. Combination immunotherapy demonstrates better efficacy in treating MSI-high CRC compared to single agent immunotherapy or chemotherapy. SUMMARY: Given improved responsiveness and overall survival, there is potential for immunotherapy to change the standard of care for metastatic CRC. Furthermore, stratifying the patients by their molecular features and mutation status is critical for establishing care.
Authors: Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André Journal: J Clin Oncol Date: 2018-01-20 Impact factor: 44.544
Authors: Tsuyoshi Hamada; Xuehong Zhang; Kosuke Mima; Susan Bullman; Yasutaka Sukawa; Jonathan A Nowak; Keisuke Kosumi; Yohei Masugi; Tyler S Twombly; Yin Cao; Mingyang Song; Li Liu; Annacarolina da Silva; Yan Shi; Mancang Gu; Wanwan Li; Hideo Koh; Katsuhiko Nosho; Kentaro Inamura; NaNa Keum; Kana Wu; Jeffrey A Meyerhardt; Aleksandar D Kostic; Curtis Huttenhower; Wendy S Garrett; Matthew Meyerson; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino Journal: Cancer Immunol Res Date: 2018-09-18 Impact factor: 11.151
Authors: David A Fabrizio; Thomas J George; Richard F Dunne; Garrett Frampton; James Sun; Kyle Gowen; Mark Kennedy; Joel Greenbowe; Alexa B Schrock; Aram F Hezel; Jeffrey S Ross; Phillip J Stephens; Siraj M Ali; Vincent A Miller; Marwan Fakih; Samuel J Klempner Journal: J Gastrointest Oncol Date: 2018-08
Authors: T T Seppälä; J P Böhm; M Friman; L Lahtinen; V M J Väyrynen; T K E Liipo; A P Ristimäki; M V J Kairaluoma; I H Kellokumpu; T H I Kuopio; J-P Mecklin Journal: Br J Cancer Date: 2015-05-14 Impact factor: 7.640
Authors: Dung T Le; Tae Won Kim; Eric Van Cutsem; Ravit Geva; Dirk Jäger; Hiroki Hara; Matthew Burge; Bert O'Neil; Petr Kavan; Takayuki Yoshino; Rosine Guimbaud; Hiroya Taniguchi; Elena Elez; Salah-Eddin Al-Batran; Patrick M Boland; Todd Crocenzi; Chloe E Atreya; Yi Cui; Tong Dai; Patricia Marinello; Luis A Diaz; Thierry André Journal: J Clin Oncol Date: 2019-11-14 Impact factor: 44.544